BMS and Gilead compete tightly in HBV drug market in KOR
By Nho, Byung Chul | translator Kim, Jung-Ju
23.06.02 06:00:08
가나다라
0
Market size KRW 200 billion... Baraclude·Viread sells KRW 69.5 billion and KRW 62.8 billion, respectively
Vemlidy posts sales of KRW 34.9 billion... Ranks 3rd and continues on its upward sales trend
Ildong Pharmacuetical's Besivo records KRW 1.7 billion in sales... is steadily increasing its share in the market
BMS’s Baraclude and Gilead Science’s Viread are fiercely competing in the KRW 200 billion original hepatitis B treatment market.
Based on drug distribution results, sales of Baraclude and Viread, the No.1 and No.2 products in the HBV market in 2022, were tallied at KRW 69.5 billion and KRW 62.8 billion, respectively.
Just last year, Baraclude’s sales slightly surpassed that of Viread, however, in 2018, 2019, and 2021, Viread (KRW 116.7 billion, KRW 83 billion, KRW 63.1 billion) posted higher sales than Baraclude (KRW 70 billion, KRW 69.8 billion, KRW 62.1 billion).
However, Gilead Sciences' steep rise in sales of its total corporate product lineup of HBV produc
Nho, Byung Chul(sasiman@dailypharm.com)
If you want to see the full article, please JOIN US (click)